anti-Nipah_007
| anti-Nipah_ID | anti-Nipah_007 |
| anti-Nipah Drug | Ac-VALDPI DISIVLN Kl KSDLEESKEWIRRSNKILDSI-GSGSGdPEG4-C-TOCO-NH2 |
| Nipah virus strain | NiV (UMMC1 ) |
| Approaches used to test anti-Nipah activity | Experimental |
| Methods used to test anti-Nipah activity | in-vivo |
| Models used to test anti-Nipah activity | African green monkeys |
| Mode of infection to test anti-Nipah activity | Intratracheal |
| Viral titer to test anti-Nipah activity | 20000000 PFU |
| Mode of Drug delivery for anti-Nipah activity | Intratracheal |
| Time of Drug delivery for anti-Nipah activity | Pre infection (1 day) |
| Duration of Drug delivery for anti-Nipah activity | 6 days |
| Drug concentration used to test anti-Nipah activity | 10 mg/kg |
| Assays used to test anti-Nipah activity | Survival assay |
| anti-Nipah activity | Increase [Percentage survival (NA NA)] |
| Survival rate of anti-Nipah compounds | 33 |
| References | Mathieu C, Porotto M, Figueira TN, Horvat B, Moscona A Fusion Inhibitory Lipopeptides Engineered for Prophylaxis of Nipah Virus in Primates. J Infect Dis. 2018 Jun 20;218(2):218-227. doi: 10.1093/infdis/jiy152. |
| Comments | The experiments provide a proof of concept for the use of antifusion lipopeptides for prophylaxis of lethal NiV |